Craneware Shares Plummet After Profit Warning Tied to 340B Drug Pricing Delays

Craneware plc (AIM: CRW.L) shares collapsed 24% on Friday, wiping out roughly a third of the healthcare software firm’s value at one point, after the Edinburgh-based company warned that FY26 results will fall well short of market expectations.

In a trading update covering the year ended 30 June 2026, Craneware said revenue would come in at $205-208 million with Adjusted EBITDA of $65-67 million — broadly flat year-on-year and materially below prior guidance. Shares fell from Thursday’s close of 1,462p to around 1,110p in early trading.

The company blamed the shortfall on the “timing” of 340B program activity — a US scheme allowing hospitals to buy discounted drugs — and the deferral of several large enterprise contracts into FY27.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Craneware said pharmaceutical manufacturers have been tightening restrictions on the supply of 340B-priced medicines, slowing the conversion of identified opportunities (with an estimated $500 million of qualifying purchases outstanding) into recognised revenue.

Because Craneware books much of this revenue only once hospitals actually receive the drugs, the impact wasn’t visible until late in the fiscal year.

Management insisted customer retention, demand and cash generation remain strong, characterizing the miss as a “short-term timing impact” rather than a structural problem, and pointed to growth in technology-enabled operational services beyond its core software.

CEO Keith Neilson said the company was “disappointed” but that “the long-term opportunity remains intact.” Full-year results are due in September 2026.

The sharp reaction underscores investor concerns about visibility and revenue recognition risk tied to Craneware’s exposure to the increasingly contentious 340B drug pricing landscape.